Now some of the key trends of challenges that will then guide the way that we deal with this pipeline issue is the emergence of targeted patient populations and therapies. And I pose this as a question. You know, is it the end of the blockbuster area? Are - is big Pharma going to be able to conti...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
